Is MannKind (NASDAQ:MNKD) a Buy or a Sell? What Does H.C. Wainwright Think?

December 12, 2017 - By reb123z

 Is MannKind (NASDAQ:MNKD) a Buy or a Sell? What Does H.C. Wainwright Think?

Why Has H.C. Wainwright Given MannKind (NASDAQ:MNKD) a $7.0 Price Target

H.C. Wainwright started its coverage for MannKind (NASDAQ:MNKD), this morning Tuesday morning. The financial firm found the stock of MNKD quite attractive and now has a target price of $7.0 with a key “Buy” rating.

MannKind Corporation (NASDAQ:MNKD) Ratings Coverage

Among 7 analysts covering Mannkind (NASDAQ:MNKD), 2 have Buy rating, 3 Sell and 2 Hold. Therefore 29% are positive. Mannkind has $9 highest and $0.05 lowest target. $3.09’s average target is 1.64% above currents $3.04 stock price. Mannkind had 15 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of MannKind Corporation (NASDAQ:MNKD) earned “Outperform” rating by RBC Capital Markets on Monday, August 3. The stock of MannKind Corporation (NASDAQ:MNKD) has “Strong-Buy” rating given on Friday, August 28 by Vetr. Griffin Securities downgraded the stock to “Neutral” rating in Monday, November 16 report. H.C. Wainwright maintained MannKind Corporation (NASDAQ:MNKD) rating on Tuesday, October 24. H.C. Wainwright has “Buy” rating and $7.0 target. As per Wednesday, September 9, the company rating was downgraded by Piper Jaffray. On Wednesday, November 8 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Wednesday, January 6, the company rating was maintained by RBC Capital Markets. The company was maintained on Friday, September 1 by Maxim Group. The firm has “Hold” rating given on Wednesday, November 1 by Maxim Group. Piper Jaffray maintained MannKind Corporation (NASDAQ:MNKD) on Wednesday, January 6 with “Underweight” rating.

The stock decreased 4.10% or $0.13 during the last trading session, reaching $3.04. About 2.02M shares traded. MannKind Corporation (NASDAQ:MNKD) has declined 75.27% since December 12, 2016 and is downtrending. It has underperformed by 91.97% the S&P500.

Analysts await MannKind Corporation (NASDAQ:MNKD) to report earnings on March, 15. They expect $-0.29 earnings per share, down 52.63 % or $0.10 from last year’s $-0.19 per share. After $-0.31 actual earnings per share reported by MannKind Corporation for the previous quarter, Wall Street now forecasts -6.45 % EPS growth.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. The company has market cap of $361.37 million. The Company’s approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It currently has negative earnings.

More notable recent MannKind Corporation (NASDAQ:MNKD) news were published by: Seekingalpha.com which released: “An Integrated BioSci Research On MannKind Corporation: How To Unlock Value?” on November 23, 2017, also Seekingalpha.com with their article: “MannKind: Insider Trading, Short Interest, And Catalysts, Oh My” published on November 16, 2017, Seekingalpha.com published: “MannKind: Afrezza Scripts Remain Flat As Holiday Season Approaches” on November 18, 2017. More interesting news about MannKind Corporation (NASDAQ:MNKD) were released by: Seekingalpha.com and their article: “MannKind: Afrezza Scripts And Revenue Rising – Is It Enough?” published on November 25, 2017 as well as Fool.com‘s news article titled: “Why MannKind Corporation Dipped 4.8% in November” with publication date: December 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.